GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » Intrinsic Value: Projected FCF

WuXi XDC Cayman (FRA:L74) Intrinsic Value: Projected FCF : €0.00 (As of May. 24, 2024)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), WuXi XDC Cayman's Intrinsic Value: Projected FCF is €0.00. The stock price of WuXi XDC Cayman is €1.69. Therefore, WuXi XDC Cayman's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for WuXi XDC Cayman's Intrinsic Value: Projected FCF or its related term are showing as below:

FRA:L74's Price-to-Projected-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.58
* Ranked among companies with meaningful Price-to-Projected-FCF only.

WuXi XDC Cayman Intrinsic Value: Projected FCF Historical Data

The historical data trend for WuXi XDC Cayman's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Intrinsic Value: Projected FCF Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - -

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of WuXi XDC Cayman's Intrinsic Value: Projected FCF

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi XDC Cayman's Price-to-Projected-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Price-to-Projected-FCF falls into.



WuXi XDC Cayman Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



WuXi XDC Cayman  (FRA:L74) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

WuXi XDC Cayman's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.69/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman (FRA:L74) Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines